LAUSR

Epidemiological evidence continues to accumulate on the effect of stress and depression with cancer initiation and progression. Depression has been introduced as an independent predictor of increased cancer mortality. Whereas early intervention for depression increases the survival rate. Even some evidence has given prognostic value for depression to predict cancer recurrence and mortality. This article presents current evidence on the correlations of molecular mechanisms of cancer and depression through; I. The evidence shows the role of pre-existing depression and anxiety in the development and progression of cancer. II. The Immune system performs a crucial role in stress, depression, and cancer. III. The role of stress and depression-induced inflammation. IV. The evidence has proposed that cancer may result in depression and the effect of depression on cancer outcome. In conclusion, the importance of preventive interventions to monitor patients' mental health during cancer treatment is very significant and should not be underestimated. In other words, the initial interventions can improve depressive symptoms and increase cancer survival. On the other hand, by identifying key biomarkers of depression, physicians can identify cancer patients who are at risk for depression or those who may not respond to routine treatments. Understanding how the cancer environment can cause pathophysiological phenomena helps develop new anti-depressant therapies and identify cancer patients that may be present during cancer. It can also help if the patients with cancer are prone to depression.